BUFFALO, NY — Gene expression profiling, combined with a novel chemoradiation regimen, may predict pathologic complete response in patients with esophageal cancer, according to research conducted at Roswell Park Cancer Institute (RPCI) and M. D. Anderson Cancer Center. Nikhil Khushalani, MD, an Assistant Professor in RPCI’s Department of Medicine, will present the preliminary results of the study Sunday, June 6, 2010 as part of the 46th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL.